Cim Investment Management Inc. Sells 12,202 Shares of Boston Scientific Corporation $BSX

Cim Investment Management Inc. trimmed its holdings in shares of Boston Scientific Corporation (NYSE:BSX) by 50.6% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 11,890 shares of the medical equipment provider’s stock after selling 12,202 shares during the period. Cim Investment Management Inc.’s holdings in Boston Scientific were worth $1,161,000 as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of the business. FWL Investment Management LLC acquired a new position in Boston Scientific during the 2nd quarter worth about $26,000. Steph & Co. acquired a new stake in Boston Scientific in the 3rd quarter valued at about $25,000. Murphy & Mullick Capital Management Corp raised its stake in shares of Boston Scientific by 200.0% in the third quarter. Murphy & Mullick Capital Management Corp now owns 255 shares of the medical equipment provider’s stock worth $25,000 after acquiring an additional 170 shares during the last quarter. Financial Consulate Inc. bought a new position in shares of Boston Scientific in the third quarter worth about $25,000. Finally, United Community Bank lifted its position in shares of Boston Scientific by 115.7% during the third quarter. United Community Bank now owns 274 shares of the medical equipment provider’s stock worth $27,000 after purchasing an additional 147 shares in the last quarter. Institutional investors own 89.07% of the company’s stock.

Analyst Ratings Changes

Several research firms have recently commented on BSX. Stifel Nicolaus decreased their price target on shares of Boston Scientific from $125.00 to $110.00 and set a “buy” rating on the stock in a research note on Wednesday, February 4th. Jefferies Financial Group reaffirmed a “buy” rating on shares of Boston Scientific in a report on Monday. Mizuho decreased their price objective on Boston Scientific from $140.00 to $115.00 and set an “outperform” rating on the stock in a research report on Thursday, February 5th. JPMorgan Chase & Co. lowered their target price on Boston Scientific from $135.00 to $100.00 and set an “overweight” rating for the company in a research note on Thursday, February 5th. Finally, TD Cowen dropped their target price on Boston Scientific from $115.00 to $100.00 and set a “buy” rating for the company in a research report on Monday, February 2nd. Two research analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and two have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $107.32.

Insider Activity at Boston Scientific

In related news, CEO Michael F. Mahoney sold 160,901 shares of the company’s stock in a transaction dated Monday, February 2nd. The stock was sold at an average price of $93.49, for a total value of $15,042,634.49. Following the completion of the sale, the chief executive officer owned 1,411,735 shares in the company, valued at approximately $131,983,105.15. This represents a 10.23% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. 0.50% of the stock is currently owned by company insiders.

Boston Scientific News Roundup

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Analyst support remains, with UBS keeping a “buy” rating despite trimming its price target — this preserves broker confidence and highlights upside vs. current levels. Benzinga
• Positive Sentiment: Market writeups note the pullback may be overdone given solid recent financials (quarterly revenue and EPS strength and guidance), which supports a rebound narrative among value- and momentum-seeking investors. Is Boston Scientific Corp. (BSX) Pull Back Overdone as Financial Results Impress?
• Positive Sentiment: News summaries explaining why BSX outpaced the market today help attract short-term flows and algos reacting to momentum and analyst notes. Why Boston Scientific (BSX) Outpaced the Stock Market Today
• Neutral Sentiment: Some investor notices and law-firm solicitations are informational and can amplify trading volume even if they don’t change fundamentals immediately; these items tend to keep the stock volatile near-term. Boston Scientific Corporation (BSX) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
• Negative Sentiment: Multiple securities class-action filings and numerous law‑firm lead‑plaintiff solicitations allege disclosure problems around the U.S. Electrophysiology unit; this raises potential litigation risk, settlement exposure and near-term headline risk that can weigh on valuation. Boston Scientific Lawsuits Put Electrophysiology Outlook And Valuation In Focus
• Negative Sentiment: Numerous law firms (Rosen, Pomerantz, Faruqi, Bernstein Liebhard, Robbins Geller, etc.) have issued alerts about the May 4 lead-plaintiff deadline — repetitive alerts keep legal risk top of mind for investors and can suppress sentiment until the cases are resolved or dismissed. INVESTOR ALERT: Pomerantz Law Firm Reminds Investors…

Boston Scientific Trading Up 2.0%

Shares of NYSE BSX opened at $71.19 on Wednesday. Boston Scientific Corporation has a fifty-two week low of $67.56 and a fifty-two week high of $109.50. The firm has a market capitalization of $105.64 billion, a P/E ratio of 36.70, a P/E/G ratio of 0.98 and a beta of 0.69. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.62 and a quick ratio of 1.08. The company’s 50 day simple moving average is $81.42 and its 200 day simple moving average is $92.71.

Boston Scientific (NYSE:BSX) last released its earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 EPS for the quarter, topping analysts’ consensus estimates of $0.78 by $0.02. The firm had revenue of $5.29 billion during the quarter, compared to analyst estimates of $5.29 billion. Boston Scientific had a net margin of 14.44% and a return on equity of 19.63%. The business’s quarterly revenue was up 15.9% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.70 EPS. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. On average, analysts predict that Boston Scientific Corporation will post 2.85 EPS for the current year.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.